China Porton Pharma Solutions, a global CDMO and XtalPi Inc., an algorithm-driven AI pharmaceutical technology company, announced the signing of a strategic cooperation agreement today. The two parties aim to carry out all-round strategic cooperation on the basis of sincere cooperation and mutual benefit
As a high standard CDMO, Porton has outstanding integrated experiences in process and crystallization R&D for innovative drugs, including a number of blockbusters, from lab scale to commercial scale manufacturing, while XtalPi possesses cutting-edge technology of Intelligent Digital Drug Discovery and Development (ID4) platform. The two parties will initiate in -depth collaboration in various fields beyond crystal structure prediction, involving crystallization R&D, intelligent drug discovery and development, and market development in biologics and drug formulation. Porton and XtalPi will work closely to integrate computing ⇔ experimentation ⇔ process development and manufacturing for better services in drug design, solid state R&D, and process development.
This collaboration should improve the efficiency of drug development and manufacturing, and let innovative drugs benefit more patients faster.
At the same time, J-Star Research, a subsidiary of Porton, signed a collaboration agreement on crystallization technologies with XtalPi’s US operation. The two sides will combine their synergetic advantages in the above-mentioned fields, and first of all develop better methodologies that can solve bottleneck problems associated with crystallization more effectively in serving drug development programs.
XtalPi has developed a series of small-molecule crystal structure prediction and drug solid-state designing and screening technology and provides innovative solutions to improve the quality and efficiency of solid-state R&D with quantum physics, computational chemistry, artificial intelligence, and cloud computing technology. In applying XtalPi‘s AI and computational chemistry tools to the bottleneck problems identified and addressed by J-Star’s subject matter experts with rich pharma crystallization R&D experiences, this collaboration will provide more reliable, efficient, and cutting-edge solutions for pharmaceutical giants and biotechs.
This strategic cooperation between Porton and XtalPi is of far-reaching significance at a time when human health is under the challenge of the COVID-19 global epidemic. Being innovationoriented enterprises, we feel it is our mission to help our clients to make effective medicines available to patients as soon as possible. At the cloud signing ceremony, Porton and XtalPi expressed their delight and expectations for fruitful strategic cooperation that will benefit theirclients in the long run.
“XtalPi is committed to the innovation and exploration of AI-powered pharmaceutical technologies with a strong focus on breakthrough research advancements with broad industry application potentials, while Porton is a leading CDMO with abundant experience in experimental research”, said Dr. Jian Ma, co-founder and CEO of XtalPi. ” In the past two years, we saw an increasing number of pharmaceutical companies that have integrated crystal structure prediction into their standard research process, especially whe n dealing with complex compounds and challenging molecular systems. We believe that combining computational technologies with targeted experiments is the future for more intelligent pharmaceutical research. XtalPi and Porton are two companies in closely related fields with complimenting skillsets. We are excited to work with Porton in combining machine-learning algorithms with high-quality experimental data to develop new prediction models that can improve upon existing research methods and address bottleneck challenges in the industry. “
“The outbreak of COVID-19 has reflected on two aspects for me. First, human beings still need to explore and reserve knowledge and technology to deal with potential major disease problems in the future. Secondly, more cooperation will be needed as the resources and capabilities of individuals are limited. It is necessary for human beings to work together to explore and cooperate in multi-disciplinary fields. Therefore, I’m glad that Porton XtalPi have reached our strategic collaboration today,” said Oliver Ju, Chairman and CEO of Porton,
“As one of the leading CDMO companies, Porton focuses on building the world’s leading pharmaceutical process R&D and manufacturing platform through our state-of-the-art technology’s platform such as crystallization, biocatalysis, complex chemistry and our customerdriven excellent service. Porton also attaches great importance to the development and application of cutting-edge technologies.
As a pioneer in the field of AI pharmaceutical technology in China, XtalPi is reinvent ing the industry’s approach to drug R&D with its Intelligent Digital Drug Discovery and Development (ID4) platform. Founded by a group of quantum physicists at MIT, XtalPi has built an elite team with multi-disciplinary expertise in physics, chemistry, pharmaceutical R&D. We believe that this strategic collaboration will combine cutting-edge scientific advances with the best practices in crystallization and formulation development to create a new benchmark for the industry in drug design and solid-state research.
We also look forward to closer cooperation between us in drug development and manufacturing to jointly explore innovative technology solutions.”